BR0110732A - Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor - Google Patents

Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor

Info

Publication number
BR0110732A
BR0110732A BR0110732-1A BR0110732A BR0110732A BR 0110732 A BR0110732 A BR 0110732A BR 0110732 A BR0110732 A BR 0110732A BR 0110732 A BR0110732 A BR 0110732A
Authority
BR
Brazil
Prior art keywords
monoclonal anti
antitumor agent
aromatase inhibitors
her2 antibodies
her2
Prior art date
Application number
BR0110732-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Giorgio Massimini
Gabriela Piscitelli
Dinesh Purandare
Original Assignee
Pharmacia Italia Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Upjohn Co filed Critical Pharmacia Italia Spa
Publication of BR0110732A publication Critical patent/BR0110732A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0110732-1A 2000-05-15 2001-04-19 Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor BR0110732A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (fr) 2000-05-15 2001-04-19 Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux

Publications (1)

Publication Number Publication Date
BR0110732A true BR0110732A (pt) 2003-02-04

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110732-1A BR0110732A (pt) 2000-05-15 2001-04-19 Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor

Country Status (20)

Country Link
EP (1) EP1282440A1 (fr)
JP (1) JP2003533490A (fr)
KR (1) KR20030014223A (fr)
CN (1) CN1429118A (fr)
AU (1) AU784617B2 (fr)
BR (1) BR0110732A (fr)
CA (1) CA2409652A1 (fr)
CZ (1) CZ20023748A3 (fr)
EA (1) EA005931B1 (fr)
EE (1) EE200200622A (fr)
HK (1) HK1054200A1 (fr)
HU (1) HUP0301877A2 (fr)
IL (1) IL152389A0 (fr)
MX (1) MXPA02011194A (fr)
NO (1) NO20025302D0 (fr)
NZ (1) NZ523004A (fr)
PL (1) PL360153A1 (fr)
SK (1) SK16022002A3 (fr)
WO (1) WO2001087334A1 (fr)
ZA (1) ZA200209815B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PL217410B1 (pl) 2000-05-19 2014-07-31 Genentech Inc Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka
EP1377298B1 (fr) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane pour traiter les troubles hormonodependants
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
KR20050059001A (ko) * 2002-07-01 2005-06-17 사비언트 파마슈티컬즈 인코퍼레이티드 치료적 처리를 위한 조성물 및 방법
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
KR20080019733A (ko) * 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
SI1850874T1 (sl) 2005-02-23 2014-01-31 Genentech, Inc. Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
WO2007045027A1 (fr) 2005-10-19 2007-04-26 Chavah Pty Ltd Réduction des effets secondaires des inhibiteurs de l'aromatase employés dans le traitement du cancer du sein
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
EP2171090B1 (fr) 2007-06-08 2013-04-03 Genentech, Inc. Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
WO2010136569A1 (fr) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
EP2643353A1 (fr) 2010-11-24 2013-10-02 Novartis AG Molécules multi-spécifiques
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
WO2013083810A1 (fr) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
WO2014015137A2 (fr) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions et méthodes de traitement de maladies dysprolifératives
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
CN107405353B (zh) 2014-10-22 2021-07-30 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
WO2017066827A1 (fr) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Procédés de réduction de la densité mammaire à la mammographie et/ou du risque de cancer du sein
EP3454863A1 (fr) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Polythérapies pour le traitement du cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
EE200200622A (et) 2004-06-15
IL152389A0 (en) 2003-05-29
SK16022002A3 (sk) 2003-04-01
AU5630901A (en) 2001-11-26
JP2003533490A (ja) 2003-11-11
CZ20023748A3 (cs) 2003-04-16
NZ523004A (en) 2004-09-24
CN1429118A (zh) 2003-07-09
HK1054200A1 (zh) 2003-11-21
AU784617B2 (en) 2006-05-18
PL360153A1 (en) 2004-09-06
NO20025302L (no) 2002-11-05
EP1282440A1 (fr) 2003-02-12
EA005931B1 (ru) 2005-08-25
ZA200209815B (en) 2003-12-03
EA200201213A1 (ru) 2003-04-24
HUP0301877A2 (hu) 2003-09-29
WO2001087334A1 (fr) 2001-11-22
NO20025302D0 (no) 2002-11-05
KR20030014223A (ko) 2003-02-15
MXPA02011194A (es) 2003-03-10
CA2409652A1 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
BR0110732A (pt) Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor
UA94899C2 (ru) Фиксированное дозирование антител к her
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
WO2002005791A3 (fr) Therapie antitumorale combinee
EP0938505A4 (fr) Anticorps monoclonaux anti-endogline et leur utilisation en therapie antiangiogenique
MXPA02010059A (es) Metodo para administrar un anticuerpo.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
BRPI0511187A (pt) método para tratar cáncer em um indivìduo
MY155603A (en) Notch-binding agents and antagonists and methods of use thereof
EA200870141A1 (ru) Комбинационная терапия с использованием антител к egfr и her2
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
EP1348466A3 (fr) Méthode de traitement du douleur avec adenosine tetraphosphates
MX2023013207A (es) Anticuerpo agonista anti-pd-1 humano para tratar o prevenir enfermedades inflamatorias, y composicion farmaceutica que contiene el mismo.
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
MY124799A (en) Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
MX2021014103A (es) Compuestos de briostatina para mejorar la inmunoterapia.
Brodie et al. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens
WO2023016826A3 (fr) Procédé et moyens pour renforcer des anticorps thérapeutiques
MX2023015469A (es) Metodos y composiciones para estimular la actividad inmunitaria.
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
WO2002100343A3 (fr) Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine-3 a utiliser dans le traitement du cancer
MX2023001481A (es) Metodos para tratar pacientes con hipercolesterolemia refractaria.
MX2022014586A (es) Métodos y composiciones para tratar la fuga vascular.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.